LCTX (Lineage Cell Therapeutics) Common Stock: $529.66 Mil (As of Mar. 2026)


LCTX Lineage Cell Therapeutics Inc LCTX
78 GF Score
Price $1.35
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Common Stock?

Lineage Cell Therapeutics LCTX +3.85% 78 Common Stock is $529.66 Mil as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review.

Lineage Cell Therapeutics's quarterly common stock increased from Sep. 2025 ($494.18 Mil) to Dec. 2025 ($515.47 Mil) and increased from Dec. 2025 ($515.47 Mil) to Mar. 2026 ($529.66 Mil).

Lineage Cell Therapeutics's annual common stock increased from Dec. 2023 ($451.34 Mil) to Dec. 2024 ($484.72 Mil) and increased from Dec. 2024 ($484.72 Mil) to Dec. 2025 ($515.47 Mil).

Lineage Cell Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics Common Stock Chart

Lineage Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 434.53 440.28 451.34 484.72 515.47

Lineage Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 489.31 490.55 494.18 515.47 529.66
LCTX
78GF Score
Lineage Cell Therapeutics Inc LCTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lineage Cell Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $529.66 Mil mean?
Lineage Cell Therapeutics (LCTX) has a Common Stock of $529.66 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lineage Cell Therapeutics and its competitors.
Is Lineage Cell Therapeutics' Common Stock too high?
Lineage Cell Therapeutics' current Common Stock is $529.66 Mil. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Common Stock compare to NWBO and ABEO?
Lineage Cell Therapeutics' Common Stock of $529.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current Common Stock is $529.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.35 — trading 1.5% above its estimated fair value. The current Common Stock is $529.66 Mil. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Common Stock is $529.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be overvalued. The current stock price of $1.35 is trading 1.5% above its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Common Stock: $529.66 Mil
  • GF Value™: $1.33 vs. price of $1.35 (1.5% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for LCTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35
Price
$1.33
GF Value